Elicio Therapeutics Inc
ELTX9.930USD
-0.050-0.50%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
158.57MCap. mercado
PérdidaP/E TTM
Más Datos de Elicio Therapeutics Inc Compañía
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). Its ELI-007, is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers. Its AMP platform has broad potential applications for the treatment or prevention of cancer, infectious diseases and other diseases.
Información de la empresa
Símbolo de cotizaciónELTX
Nombre de la empresaElicio Therapeutics Inc
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoMr. Robert (Bob) Connelly
Número de empleados32
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 05
Dirección451 D Street, 5Th Floor
CiudadBOSTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02459
Teléfono18572090050
Sitio Webhttps://elicio.com/
Símbolo de cotizaciónELTX
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoMr. Robert (Bob) Connelly
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-5.71%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
381.00
--
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
Ms. Carol Ashe
Ms. Carol Ashe
Independent Director
Independent Director
--
--
Dr. Allen R. Nissenson, M.D.
Dr. Allen R. Nissenson, M.D.
Independent Director
Independent Director
--
--
Dr. Robert R. Ruffolo, Jr.
Dr. Robert R. Ruffolo, Jr.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Connelly
Mr. Robert (Bob) Connelly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-5.71%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
381.00
--
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 1 de ago
Actualizado: vie., 1 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
GKCC, LLC
33.86%
Actyus Private Equity SGIIC, S.A.
5.35%
Knoll Capital Management, LLC
3.94%
Clal Biotechnology Industries Ltd
3.01%
The Vanguard Group, Inc.
2.01%
Other
51.82%
Accionistas
Accionistas
Proporción
GKCC, LLC
33.86%
Actyus Private Equity SGIIC, S.A.
5.35%
Knoll Capital Management, LLC
3.94%
Clal Biotechnology Industries Ltd
3.01%
The Vanguard Group, Inc.
2.01%
Other
51.82%
Tipos de accionistas
Accionistas
Proporción
Corporation
39.21%
Hedge Fund
5.54%
Investment Advisor/Hedge Fund
3.32%
Holding Company
3.01%
Individual Investor
1.65%
Investment Advisor
0.97%
Research Firm
0.33%
Bank and Trust
0.11%
Other
45.86%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
59
8.71M
54.45%
+612.65K
2025Q1
71
8.88M
57.84%
+3.95M
2024Q4
66
3.95M
32.81%
+187.04K
2024Q3
70
4.16M
40.61%
+80.64K
2024Q2
82
4.28M
44.94%
+434.22K
2024Q1
108
4.00M
44.25%
+126.75K
2023Q4
114
4.22M
52.86%
+1.57M
2023Q3
132
2.88M
52.57%
+376.65K
2023Q2
138
2.82M
63.05%
+1.05M
2023Q1
137
1.45M
48.19%
-243.12K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
GKCC, LLC
5.42M
33.86%
--
--
Jun 03, 2025
Actyus Private Equity SGIIC, S.A.
856.38K
5.35%
+268.56K
+45.69%
Mar 31, 2025
Knoll Capital Management, LLC
630.91K
3.94%
--
--
Mar 31, 2025
Clal Biotechnology Industries Ltd
481.73K
3.01%
-52.31K
-9.80%
Apr 09, 2024
The Vanguard Group, Inc.
321.69K
2.01%
+75.87K
+30.86%
Mar 31, 2025
Hudson Bay Capital Management LP
182.73K
1.14%
+182.73K
--
Mar 31, 2025
Venkatesan (Jay R)
170.22K
1.06%
-10.31K
-5.71%
Mar 24, 2025
Geode Capital Management, L.L.C.
77.47K
0.48%
+6.75K
+9.54%
Mar 31, 2025
CM Management, LLC
55.00K
0.34%
+15.00K
+37.50%
Mar 31, 2025
Millennium Management LLC
52.22K
0.33%
+52.22K
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
iShares Micro-Cap ETF
Proporción0.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
Fecha
Tipo
Relación
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
